Exenatide elicits sustained glycemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin
The return on investment for sleep optimization is enormous
21,24,25 In some instances, patients may remain on the lowest effective dose and only escalate as needed, such as when weight reduction plateaus
Existing extended-release options, like weekly formulations of semaglutide and dulaglutide, have reduced injection frequency, and future innovations may include monthly formulations or implantable devices that deliver continuous therapy
Moreover, the greater lean mass and mechanical loading typically observed in males may provide partial protection against CR-induced bone resorption
Such supplements may also be comparatively inexpensive